Abstract:ARNI (Sacubitril / Valsartan) is known to have natriuretic effects in addition to vasodilatory effects, cardiac hypertrophy, and antifibrosis. Therefore, it is considered to have a great effect on blood pressure and is used as an antihypertensive drug. However, the details of improvement of blood pressure changes in CKD patients are clearly unknown. Here we examine the clinical effects of ARNI administration in CKD patients by stage of renal function. 41 CKD patients who started enresting for hypertension from September 27, 2021 to February 28, 2022, and 26 of them were able to follow up for a period of 3 months or more after oral administration. Patient profiles by renal function are 9 persons stage G3 (eGFR30–59), 4 persons stage G4 (eGFR15–29), 9 persons stage G5 (less than eGFR15), 3 persons stage G5D (during dialysis) PD, and 1 person HD + PD. Blood Pressure, eGFR, protein quantification, and NT-proBNP are measured before and after administration for a period of 3 months or more, and analysis was performed by two-way ANOVA with a mixed model using SPSS. In addition, ABPM was performed before and after ARNI administration in 9 of them (6 treatment-resistant hypertension), and the diurnal variation pattern, changes in proteinuria and renal function were also examined. Before and after ARNI administration, blood pressure decreased and edema improved in most patients. There was no interaction with the rate of decrease in GFR (significance probability 0.972). In addition, urinary protein increased to 1.57 g/gCre (mean difference 95% confidence interval 0.175–2.966, significance probability 0.006 interaction). NT-proBNP decreased before and after administration. In stage G3, the dipper type of ABPM did not change, and the non-dipper type improved slightly. In stage G5 it was improved the degree of descent at night, and a change in category. However, in the case of peritoneal dialysis, the mean blood pressure did not improve, and the effect of pattern improvement was not observed. ARNI was found to exert a strong antihypertensive effect on CKD patients that has not been treated with dialysis. And ARNI did not affect the antihypertensive effect even if there is residual urine during the dialysis period. In addition, edema can be expected to have a reducing effect regardless of proteinuria, and if blood pressure can be lowered firmly, it can also be expected to have a reducing effect on proteinuria.

Effects of Azelnidipine on Uric Acid Metabolism in Patients with Essential Hypertension

Effect of Switching from Cilnidipine to Azelnidipine on Cardiac Sympathetic Nerve Function in Patients with Heart Failure Preserved Ejection Fraction

Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia

Serum Uric Acid Change in Relation to Antihypertensive Therapy with the Dihydropyridine Calcium Channel Blockers

Clinical Use of Azelnidipine in the Treatment of Hypertension in Chinese Patients

Effect Of Uric Acid-Lowering Therapy On Blood Pressure: Systematic Review And Meta-Analysis

PS-C19-9: CLINICAL EFFECTS OF ARNI (SACUBITRIL/VALSARTAN) IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH HYPERTENSION

The effects of replacing dihydropyridine calcium-channel blockers with angiotensin II receptor blocker on the quality of life of hypertensive patients

Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients

Serum uric acid-lowering effect of sacubitril/valsartan in hypertensive patients: evaluation by switching from angiotensin II receptor blockers

[The Effects of Aranidipine on Ambulatory Blood Pressures in Patients with Mild to Moderate Essential Hypertension].

Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study

Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice

[Effect of Benidipine on Plasma Level of Calcitonin Gene-Related Peptide in Essential Hypertension].

Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial.

Calcium Channel Blockers, More Than Diuretics, Enhance Vascular Protective Effects of Angiotensin Receptor Blockers in Salt-Loaded Hypertensive Rats

Effects of Cilnidipine on Fibrinolysis in Chinese Hypertensive Patients

Effects of uric acid on vascular endothelial function from bedside to bench

Dual Actions of Cilnidipine in Human Internal Thoracic Artery: Inhibition of Calcium Channels and Enhancement of Endothelial Nitric Oxide Synthase.

Renal protection effects of benidipine in patients with hypertension: meta-analysis

A meta-analysis of anti-hypertensive efficacy and safety between cilnidipine and amlodipine